Previous Article | Next Article ![]()
Infection and Immunity, July 2005, p. 4062-4069, Vol. 73, No. 7
0019-9567/05/$08.00+0 doi:10.1128/IAI.73.7.4062-4069.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
B. Chatrenet,2
A. Gauvrit,3
F. Aviat,1
A. Aubert,2
J. M. Bach,3 and
G. André-Fontaine1*
Leptospira Medical and Molecular Bacteriology Unit, Ecole Nationale Vétérinaire de Nantes, BP 40706, 44307 Nantes cedex 03, France,1 Virbac Laboratories, BP 27, 06511 Carros Cedex, France,2 Immuno-endocrinology Unit, ENVN/INRA/University, BP 40706, 44307 Nantes cedex 03, France3
Received 4 October 2004/ Returned for modification 17 November 2004/ Accepted 3 March 2005
The use of DNA constructs encoding leptospiral proteins is a promising new approach for vaccination against leptospirosis. In previous work we determined that immunization with hemolysis-associated protein 1 (Hap1) (LipL32) expressed by adenovirus induced significant protection against a virulent Leptospira challenge in gerbils. To avoid the use of the adenovirus vector, we checked for clinical protection against lethal challenge by DNA vaccination. A DNA vaccine expressing Hap1 was designed to enhance the direct gene transfer of this protein into gerbils. A challenge was performed 3 weeks after the last immunization with a virulent strain of serovar canicola. Our results show that the cross-protective effect with pathogenic strains of Leptospira, shared by Hap1, could be mediated by the DNA plasmid vector. This finding should facilitate the design and development of a new generation of vaccines against bacteria, particularly Leptospira interrogans sensu lato.
Present address: Department of Biology, Washington University, 1 Brookings Dr., Campus Box 1137, St. Louis, MO 63130.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»